non-small cell lung cancer

Akeso's lung cancer drug ivonescimab showed better-than-expected clinical results for treating a type of lung cancer common in smokers. Analysts believe it could become a backbone therapy in the US$20 billion global non-small cell lung cancer market and raised target prices. Phase three trials found the drug reduced the risk of death.

Akeso's drug ivonescimab showed better-than-expected clinical results for treating a type of lung cancer common in smokers, potentially expanding its approved uses. Analysts predict it could become a backbone therapy in the US$20 billion global non-small cell lung cancer market, with revised upward target prices.

A new study suggests GLP-1 weight-loss drugs like semaglutide and tirzepatide may significantly slow the progression of obesity-related cancers such as lung, breast, colorectal, and liver cancers. Conducted by Cleveland Clinic and to be presented at the 2026 ASCO Annual Meeting, the retrospective analysis found GLP-1 users had up to 50% lower risk of cancer advancing to stage 4 compared to patients taking DPP-4 inhibitors.

Merck and China-based Kelun-Biotech's drug sacituzumab tirumotecan demonstrated a 65% reduction in tumor progression risk in Phase 3 lung cancer trials. The study represents the first successful combination of an antibody-drug conjugate with PD-1 immunotherapy in advanced non-small cell lung cancer patients, with preliminary survival benefits observed.

A study published in Nature uses DNA-sequencing data from primary tumors and paired metastases in the TRACERx lung study and PEACE autopsy program to analyze metastatic diversity and seeding patterns in advanced non-small cell lung cancer.